Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Estrella Immunopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Estrella Immunopharma's regulatory disclosures and financial reporting.
Estrella Immunopharma, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the registration statement unchanged and focuses on updating the list of exhibits.
The filing itemizes corporate documents such as the amended and restated charter and bylaws, various merger and financing agreements, equity incentive plans, employment agreements, and a warrant agreement, largely incorporated by reference from earlier filings. It also includes the legal opinion from Winston & Strawn LLP, consents from current and former auditors, XBRL-related exhibits, and powers of attorney.
The amendment is signed on behalf of Estrella Immunopharma by Chief Executive Officer Cheng Liu and lists the company’s principal officers and directors, confirming their authorization of the registration statement.